Head-To-Head Contrast: Promis Neurosciences (NASDAQ:PMN) & Bavarian Nordic (OTCMKTS:BVNRY)

Promis Neurosciences (NASDAQ:PMN) and Bavarian Nordic (OTCMKTS:BVNRY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Institutional and Insider Ownership

50.1% of Promis Neurosciences shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Promis Neurosciences has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500. Comparatively, Bavarian Nordic has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.

Profitability

This table compares Promis Neurosciences and Bavarian Nordic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Bavarian Nordic	19.74%	9.37%	8.10%

Analyst Ratings

This is a summary of recent ratings and price targets for Promis Neurosciences and Bavarian Nordic, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1	0	2	1	2.75
Bavarian Nordic	0	0	0	0	0.00

Promis Neurosciences presently has a consensus target price of $26.50, suggesting a potential upside of 150.21%. Given Promis Neurosciences’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Promis Neurosciences is more favorable than Bavarian Nordic.

Valuation and Earnings

This table compares Promis Neurosciences and Bavarian Nordic”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72 million	($14.51)	-0.73
Bavarian Nordic	$945.43 million	2.42	$208.23 million	$0.76	12.67

Bavarian Nordic has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Bavarian Nordic, indicating that it is currently the more affordable of the two stocks.

Summary

Bavarian Nordic beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

About Promis Neurosciences

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.